In an alliance with the US National Institute for Allergy and Infectious Diseases, Lilly’s JAK1/2 inhibitor for rheumatoid arthritis Olumiant (baracitinib) is being investigated for anti-inflammatory benefit in COVID-19 patients, with data expected in June

A Phase II trial of LY3127804, an antibody against angiopoietin 2, which is known to be elevated in patients with acute respiratory distress syndrome, is enrolling patients with COVID-19-associated pneumonia. Data are expected in June

Lilly is collaborating with AbCellera to assess therapeutic potential of antibodies in patients who recovered from the virus, with a goal of filing an investigational new drug (IND) application in May

Lilly Saw Pandemic-Related Benefits In Q1, Expects Headwinds Long Term

More from Earnings

More from Business